Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide

Castration‐resistant prostate cancer (CRPC) is the latest stage of PCa, and there is almost no effective treatment available for the patients with CRPC when next‐generation androgen deprivation therapy drugs, such as enzalutamide (ENZ), fail. The androgen receptor (AR) plays key roles in PCa and CRP...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Zhe, Xiang, Zhendong, Zhang, Pan, Wu, Qiang, Xu, Chengdang, Wang, Xinan, Shi, Guowei, Hong, Zongyuan, Wu, Denglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299045/
https://www.ncbi.nlm.nih.gov/pubmed/34323404
http://dx.doi.org/10.1002/ctm2.495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299045/
https://www.ncbi.nlm.nih.gov/pubmed/34323404
http://dx.doi.org/10.1002/ctm2.495

Ejemplares similares